Borden Lacy Archive — Page 1 of 1

C. difficile bacteria (image courtesy of CDC/Jennifer Oosthuizen)
February 18, 2026

Vanderbilt research offers new hope for preventing repeated C. diff infections

Treatment options are limited for the more than 500,000 people in the U.S. who are diagnosed annually with C. diff infections, but researchers are working on potential vaccines, therapeutic antibodies and — most recently — nanobodies, to prevent and treat C. diff infections.

February 18, 2026

Novel vaccine protects against C. diff disease and recurrence

New study represents a major step forward for vaccine development for C. diff, the leading cause of health care- and antibiotic-associated infection.

The study team includes, from left, Maribeth Nicholson, MD, MPH, Ben Spiller, PhD, Buddy Creech, MD, MPH, Borden Lacy, PhD, Eric Skaar, PhD, MPH, Isaac Thomsen, MD, MSCI, Ivelin Georgiev, PhD, and Danyvid Olivares-Villagomez, PhD.
March 30, 2023

NIH grant launches C. diff vaccine research initiative

Vanderbilt has received an NIH grant to launch the Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile Vaccines, or VANDy-CdV.

January 10, 2020

Structural views of a C. diff toxin

D. Borden Lacy and colleagues used cryo-electron microscopy to define the structure of a C. diff toxin, providing a framework for the design of novel therapeutics.

July 11, 2019

Vanderbilt team shows how stomach bug can trigger cancer

Researchers at Vanderbilt University and the University of Michigan in Ann Arbor have obtained the first high-resolution image of a molecular “machine” used by the insidious stomach bug Helicobacter pylori (H. pylori) to inject a cancer-causing protein into the stomach lining.

Clostridium difficile bacterium, 3D illustration
January 26, 2018

Versatile C. difficile blocker

New research reveals a unique mechanism of C. difficile toxin neutralization by a monoclonal antibody, suggesting new therapeutic approaches.